Nicox’s partner, Ocumension Therapeutics, submits a New Drug Application for ZERVIATE in China ZERVIATE® approval and launch expected ...
Agreement with the Commonwealth of Pennsylvania supports expansion of manufacturing capacities for the semiconductor industry The roughly € 300 mil...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation ...
During aging, the central nervous system (“CNS”) becomes more inflammatory, leading to activation of microglia (“CNS immune cells&rdquo...
The published data showcase how Evaxion's proprietary AI-platform, RAVEN (Rapidly Adaptive Viral Response), identifies broad and robust T-cell epitopes fro...
Ocutrx Technologies, a global technology company developing revolutionary medical devices with augmented reality (AR), extended reality (XR) and artificial...
The RecMap is available here = https://covid19.recmap.org The RecMap is a one-stop shop for clinical, public health and health policy COVID-19 recommendat...
Samsung Ventures makes investment in Araris Proceeds will be used to support further development and advancement of Araris’ antibody-drug conjugat...
Agilent Technologies Inc. (NYSE: A) announced the latest addition to the Cary 3500 UV-Vis Series with the release of the Agilent Cary 3500 Flexible U...
Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose therapies to its Bourgoin, France site,...
The project will see the site’s footprint increase by 32,000 square feet (3,000 square meters) to add capacity for the storage and handling of clinic...
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune ...
Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike...
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- -Vertex Pharmac...
© 2024 Biopharma Boardroom. All Rights Reserved.
